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therapyAmong the various extrahepatic manifestations of hepatitis
C virus (HCV) infection, Type 2 diabetes mellitus (DM) is
one of the most common diseases associated with chronic
HCV. There are strong lines of evidence supporting an
epidemiologic link between DM and chronic hepatitis C
(CHC). The higher prevalence of DM in CHC patients is
observed all over the world. In Taiwan, large-scale studies
have been reported showing the higher accumulated risk
for DM in individuals with positive anti-HCV and the
important role of HCV viremia, but not anti-HCV seropos-
itivity alone, on the increased association with DM. With a
prediabetic condition, namely, impaired fasting glucose
and/or impaired glucose tolerance, oral glucose tolerance
test can be used to diagnose DM more accurately; in fact,
an additional 18.6% of DM patients who were diagnosed as
having DM by oral glucose tolerance test were not initially
considered to have DM based on fasting sugar level alone
[1]. Insulin regulates glucose homeostasis, and insulin
resistance (IR)dmeasured by the “gold standard” hyper-
insulinemiceeuglycemic clamp, or alternatively by the
homeostasis model assessment-IR (HOMA-IR), which is used
clinicallydhas a pivotal role in the pathogenesis of DM. IR
has been reported to develop early in the course of HCV
infection, and increased HOMA-IR was associated with
more advanced fibrosis [2]. There was also a dos-
eeresponse relationship between HCV RNA level and the
presence of IR reported in Taiwan [3], which implicated
the strong association between HCV and glucose
metabolism.
Peginterferon alfa (PEG-IFN)/ribavirin combination
therapy has remained the standard treatment regimen,
especially in Asian countries despite the rapid develop-
ment of novel direct-acting antivirals (DAAs), which are
generally expensive. In Taiwan, the response-guided
therapy is applied with a higher sustained virological
response (SVR) rate for Genotype 1 (76e80%) and Geno-
type 2 (95%) compared with that used for patients in
Western countries. The influence between IR or DM and
antiviral therapy with PEG-IFN/ribavirin is interesting.http://dx.doi.org/10.1016/j.aidm.2016.03.004
2351-9797/Copyrightª 2016, The Gastroenterological Society of Taiwan
for the Study of the Liver. Published by Elsevier Taiwan LLC. This is
creativecommons.org/licenses/by-nc-nd/4.0/).Previous studies have shown the negative impact of DM
on the response to PEG-IFN/ribavirin [4]. Similarly,
studies have shown that IR is associated with a higher
likelihood of failure to achieve an SVR in patients with
different genotype infection [5,6]. Actually, the impact
of IR on SVR has been reported in some special subgroups
of patients, for example, difficult-to-treat patients,
different HCV genotypes or races [7,8]. The specific as-
sociation between lower IR and better response has
made it possible to increase the SVR by targeting and
improving the metabolic profiles related to IR, such as
lifestyle modification or medications, prior to antiviral
treatment.
For PEG-IFN/ribavirin therapy in CHC, another inter-
esting issue is the impact of antiviral therapy on IR. With
an existing property of immune modification, the emer-
gence of IR and subsequent DM has been demonstrated
with interferon-based therapy [9]. However, HCV core
protein has a direct effect in inhibiting the insulin
signaling pathway by upregulating suppressor cytokine
signaling-3 or by dephosphorylation of AKT, a ser-
ine/threonine protein kinase B. Viral clearance might
lead to improvement in insulin sensitivity and to glycemic
control. Several studies have reported that reduced IR
and subsequent improved glucose control after IFN
therapy had been observed among patients with CHC who
achieved SVR [10]. In Taiwan, our previous studies have
shown that there was no significant decline in HOMA-IR
even among those who achieved SVR. The significant
decline of HOMA-IR after treatment was observed only in
those patients with high pretreatment HOMA-IR, irre-
spective of SVR achievement [11], and successful eradi-
cation of HCV improves glucose abnormalities in
prediabetic CHC patients [12]. In nondiabetic Taiwanese
patients with CHC after Peg-IFN/ribavirin therapy, we
have reported the insignificant decline of HOMA-IR in
those responders. Nevertheless, a significant relief of
pancreatic beta-cell function measured by the HOMA
model (HOMA-%B: fasting insulin level (mU/mL), The Digestive Endoscopy Society of Taiwan and Taiwan Association
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38 Editorial360/fasting plasma glucose (mg/dl)63) was noted, which
may implicate the recovery in pancreatic beta-cell
function earlier than that of IR after the response to
Peg-IFN/ribavirin therapy [11].
In the current issue of the Advances of Digestive
Medicine journal, Tseng et al investigated the change in
IR from baseline, through the end of, and up to 24 weeks
after the standard regimen with PEG-IFN plus ribavirin in
65 Taiwanese patients with CHC [13]. With the regimen of
the National Health Insurance, which commenced in
1995, the current reimbursement for PEG-IFN/ribavirin
therapy in Taiwan is as follows: 24 weeks for PEG-IFN/
ribavirin for patients with a rapid virological response
(RVR), 48 weeks for patients without an RVR and with a
early virological response (EVR), and 16 weeks (the
stopping rule) for patients without an EVR [14]. Forty-six
(71%) patients achieved SVR. When the authors compared
the changes in HOMA-IR and body mass index (BMI) during
and after the antiviral therapy, a significant decrease in
HOMA-IR was noted in patients with SVR (median value of
3.6, 1.4, and 1.3 at baseline, end of therapy, and 24
weeks after completing the therapy, respectively), but
not in those without SVR (median value of 3.9, 2.1, and
2.2 at baseline, end of therapy, and 24 weeks after
completing the therapy, respectively). With a significant
decrease in BMI at the end of the therapy compared with
baseline data in all treated 65 patients [median value (in
kg/m2): 25.1 and 23.2 at baseline and end of therapy; for
SVR patients, 24.4 and 22.9, and for non-SVR patients,
26.0 and 24.3, respectively], a significant decrease in BMI
at 24 weeks after completing the therapy (compared with
baseline data) was in contrast noted in patients without
SVR (25.9 kg/m2) but not in those with SVR (24.3 kg/m2)
at baseline, at the end of the therapy, and 24 weeks after
completing the therapy, respectively. The authors
concluded that antiviral therapy improves IR during HCV
treatment, and the effectiveness in decreasing IR persists
only in patients who achieve an SVR. Despite the limi-
tationsdthe small number of cases, the lack of stratifi-
cation of the pretreatment IR status by clinical diagnosis
of DM or the medication, the results of improved IR
without decrease of the BMI in patients with SVR support
the role of antiviral therapy and the association between
viremia and IR. Incidentally, the results of “insignificant”
change in IR at 24 weeks after completing the therapy
(3.9 to 2.2) with a significant decrease in BMI (26 to 25.9)
in patients without SVR warrant further investigation as
only 19 patients were enrolled in the study. Further large-
scale studies with stratification of patients with different
pretreatment IRs are necessary.
Anti-HCV therapy has experienced a tremendous
progress in recent years. Several DAAs including three
groups (viral protease NS3/4A inhibitors, viral RNA-
dependent RNA-polymerase NS5B inhibitors, and the
replicon complex NS5A inhibitors) have been approved,
and interferon-free antiviral treatments have become
available that achieve SVRs of more than 80e90% for
most treatment groups. It is believed that in the near
future, most patients with CHC will achieve virological
clearance with the DAAs, enabling achievement of high
SVR rates. Because DAAs have a different mechanism
of anti-HCV effect, the association between the IR/glucose metabolism and the effectiveness, clinical
course, and long-term outcomes deserve to be
elucidated.
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